Given that the reduced NO bioactivity is a hallmark of endothelial dysfunction, our findings indicate that Y-T2D plasma–derived small ECVs contribute to endothelial dysfunction by inhibiting eNOS activity and reducing NO levels in Y-T2D. This evidence concerns the gene NOS3 and endothelial dysfunction.